The present invention relates to: a pharmaceutical composition for preventing or treating ischemic diseases, containing liposomes into which vascular endothelial growth factor (VEGF)-derived peptides are loaded; a method for treating ischemic diseases, comprising the step of administering the pharmaceutical composition to an individual suspected of having an ischemic disease; a use of the liposomes; and a kit for evaluating, using the liposomes, the amount of liposomes, into which VEGF-derived peptides are loaded, delivered to ischemic lesions and of loaded materials released and absorbed. The composition, of the present invention, for preventing or treating ischemic diseases, containing liposomes into which VEGF-derived peptides are loaded, the liposomes having an average particle size of 90 to 110 nm and a particle distribution of 50 to 200 nm and being surface-modified with polyethylene glycol, is capable of significantly increasing the absorption of VEGF compared with treatment using solely VEGF, thereby effectively treating ischemic diseases such as myocardial infarction, middle cerebral artery stenosis, lower limb ischemia, and cerebral infarction. In addition, the kit provided in the present invention can be useful in evaluating the amount of liposomes, into which VEGF-derived peptides are loaded, delivered to ischemic lesions and of loaded materials released and absorbed, in a treatment step for a patient with ischemic diseases.

The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.

Provided is a probe for detecting in vivo hydrogen sulfide, specifically, a probe for detecting hydrogen sulfide including a complex compound into which a radioactive isotope Cu is introduced. According to specific embodiments of the present disclosure, as a result of real-time observing animal models, in which hydrogen sulfide involved in various diseases is generated in a large quantity, through optical and nuclear medicine imaging, the probe for detecting hydrogen sulfide according to the present disclosure may selectively bind with hydrogen sulfide to provide images of a site where hydrogen sulfide has abnormally increased in a cell or a tissue, thereby detecting a disease in an unexpected site without affecting the anatomical properties of the body. Accordingly, the probe may be effectively used as a means for diagnosing diseases, such as a composition for imaging, an imaging method, etc.

The invention provides a method of preparing a .sup.89Zr-oxine complex of the formula. The invention also provides a method of labeling a cell with the .sup.89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the .sup.89Zr-oxine complex to the subject. ##STR00001##

Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives a stable .sup.99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.

The present invention relates to conjugates comprising a chelator arranged for complexation of a radionuclide and a targeting moiety binding to LRRC15. For example, the conjugates according to the current invention can be targeted alpha therapeutics such as targeted thorium conjugates (TTCs), i.e. radioconjugates comprising an alpha emitter, such as .sup.227Th. The present invention further relates to sequence-defined antibodies binding LRRC15 and antigen-binding fragments thereof. Also provided are conjugates comprising these antibodies or functional fragments thereof. The antibodies, functional fragments and conjugates according to the current invention can be used to treat cancer and other disorders and conditions associated with the expression of LRRC15.